John Miller, MD
Psychiatry · Exeter, NHNPI 1841307527
Payments from drug & device makers
Across 3,360 payments — averaging $808.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$478K
- Otsuka America Pharmaceutical, Inc.$441K
- Neurocrine Biosciences, Inc.$353K
- Teva Pharmaceuticals USA, Inc.$325K
- Axsome Therapeutics, Inc.$318K
- AbbVie$274K
- plus $526K from 14 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 526 | $478,436 |
| Otsuka America Pharmaceutical, Inc. | 615 | $440,853 |
| Neurocrine Biosciences, Inc. | 372 | $352,978 |
| Teva Pharmaceuticals USA, Inc. | 282 | $325,166 |
| Axsome Therapeutics, Inc. | 306 | $318,190 |
| AbbVie(2 entities) | 418 | $274,242 |
| E.r. Squibb & Sons, L.L.C. | 183 | $197,441 |
| Johnson & Johnson | 258 | $174,704 |
| Sunovion Pharmaceuticals Inc. | 265 | $131,379 |
| Janssen Research & Development, LLC | 15 | $8,336 |
| Boehringer Ingelheim | 14 | $7,142 |
| Biogen | 4 | $2,701 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 12 | $2,688 |
| Alkermes, Inc. | 53 | $878 |
| Vanda Pharmaceuticals Inc. | 21 | $497 |
| Lundbeck LLC | 10 | $184 |
| Sage Therapeutics, LLC | 1 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Janssen Scientific Affairs, LLC | 1 | $12 |
How this compares
$2,715,944 in reported general payments places this provider in the 95th percentile of 166 psychiatry providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Exeter
- Paul BelliveauExeter$9K
- Andrew KaplanExeter$3K
- Erika WilsonExeter$2K
- Stephen EllenNashua$1.4M
- Robert CotesLebanon$906K
- Michael McNamaraManchester$757K
- Hisham HafezNashua$330K
- Kenneth BrownBrentwood$94K
- Janet CarellaManchester$82K
- Ashwini SaxenaManchester$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.